Infectious Disease · Dengue Therapeutics
Aedion Therapeutics is advancing a globally protected antiviral programme for dengue — an infection that affects 400 million people annually with no approved treatment.
Aedion Therapeutics was founded not to start from zero, but to capture, protect, and advance an existing body of scientific and clinical work. Built around exclusive global rights to VMD55 and grounded in the pioneering research of Professor Max Reynolds, the company is designed to convert promising science into a durable therapeutic asset.
The company combines rigorous IP strategy, disciplined regulatory and clinical execution, and a global commercial structure — credible to institutional investors, strategic partners, and regulators across priority dengue-endemic markets.
"By securing exclusive global rights, centralising know-how, and building a focused regulatory and clinical pathway, Aedion seeks to convert promising science into a durable therapeutic asset."
VMD55 is Aedion's lead asset, held under a global exclusive licence and supply framework. The programme builds directly on a completed Phase III clinical trial conducted in Indonesia, in which the predecessor compound to VMD55 demonstrated significant antiviral activity against dengue virus, a strong safety profile, and capacity to prevent plasma leakage — the defining complication of severe dengue.
| Study Type | Phase III clinical trial — Indonesia |
| Primary Finding | Significant reduction in viral load following treatment; antiviral activity against dengue virus confirmed |
| Endothelial Effect | Demonstrated capacity to maintain endothelial homeostasis, preventing plasma leakage — a hallmark of severe dengue |
| Safety Profile | Well tolerated; no hepatotoxic or nephrotoxic effects identified; no other significant adverse effects observed |
| Study Conclusion | The predecessor compound to VMD55 was concluded to be suitable for adoption as standard treatment for dengue patients |
| Asset | VMD55 |
| Primary Indication | Dengue |
| Future Expansion | Adjacent high-burden viral diseases |
| Rights Structure | Global exclusive licence and supply framework — single global holder |
| Scientific Origin | Pioneering research programme of Professor Max Reynolds |
| Development Stage | Pre-clinical to clinical pathway; priority markets identified |
| IP Strategy | Active protection and strategic expansion of surrounding intellectual property |
| Quality Standard | GMP-aligned international quality development pathway |
Institutional enquiries, data room access, and investor documentation available on request.